Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14166026 | 0.98 | BCHE (0.67) | BCHEMEN1TSHRKMT2ASIGMAR1 | |
| SCHEMBL8313882 | 0.89 | BCHE (0.70) | BCHEMEN1TSHRKMT2ASIGMAR1 | |
| SCHEMBL186785 | 0.86 | BCHE (0.67) | BCHEMEN1TSHRKMT2ASIGMAR1 | |
| SCHEMBL4135213 | 0.86 | BCHE (0.67) | BCHEMEN1TSHRKMT2ASIGMAR1 | |
| SCHEMBL8550490 | 0.85 | BCHE (0.65) | BCHEMEN1KMT2AOPRK1ACHE | |
| Hydrochloric Acid SCHEMBL22587709 | 0.85 | BCHE (0.65) | BCHEMEN1TSHRKMT2ASIGMAR1 | |
| Hydrochloric Acid SCHEMBL9380707 | 0.85 | BCHE (0.65) | BCHEMEN1TSHRKMT2ASIGMAR1 | |
| Hydrochloric Acid SCHEMBL8556315 | 0.84 | MEN1 (0.65) | BCHEMEN1KMT2AOPRK1ACHE | |
| Hydrochloric Acid SCHEMBL10969823 | 0.84 | BCHE (0.64) | BCHEMEN1TSHRKMT2ASIGMAR1 | |
| SCHEMBL27780812 | 0.84 | BCHE (0.64) | BCHESIGMAR1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0302787-B1 | 2-Methyl(4-piperidinyl)-benzofuro[2,3-c] pyridines, their preparation and therapeutical use | SYNTHELABO (FR) | 1991-10-30 | — | — | EP | claimed |
| EP-2718280-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMA SPA (IT) | 2015-09-16 | — | — | EP | disclosed |
| US-8877774-B2 | Compounds having muscarinic receptor antagonist and beta2 Adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-11-04 | — | — | US | disclosed |
| US-8877774-B2 | Compounds having muscarinic receptor antagonist and beta2 Adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-11-04 | — | — | US | disclosed |
| US-20130045169-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-02-21 | — | — | US | disclosed |
| WO-2012168359-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-12-13 | — | — | WO | disclosed |
| EP-1786819-B1 | DIHYDROPTERIDINONE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2011-01-26 | — | — | EP | disclosed |
| EP-1786819-A1 | DIHYDROPTERIDINONE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006021379-A1 | DIHYDROPTERIDINONE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-02 | — | — | WO | disclosed |
| EP-1630163-A1 | Dihydropteridinones, methods for their preparation and their use as drugs | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2006-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045169-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | BCHE 571/4885MEN1 3379/4885TSHR 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.